BNP Paribas Financial Markets
GANX icon

BNP Paribas Financial Markets’s Gain Therapeutics GANX Stock Holding History

BNP Paribas Financial Markets’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,381
Closed -$7.67K – 5938
2025
Q4 		$7.67K Buy
+2,381
New +$6.35K ﹤0.01% 5204
2022
Q4 		– Sell
-283
Closed -$923 – 4255
2022
Q3 		$923 Buy
+283
New +$1.06K ﹤0.01% 4439

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BNP Paribas Financial Markets's GANX Position: Q1 2026 in Review

BNP Paribas Financial Markets sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 2,381 shares — an estimated $7.67K sold.

BNP Paribas Financial Markets first reported a position in GANX in Q3 2022 and held it in 2 quarters. The position peaked at $7.67K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • BNP Paribas Financial Markets reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 2,381 Gain Therapeutics shares in Q1 2026, an estimated $7.67K.
  • BNP Paribas Financial Markets first reported a position in Gain Therapeutics in Q3 2022 and held it in 2 quarters.
  • BNP Paribas Financial Markets's Gain Therapeutics position peaked at $7.67K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.